Cargando…
Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting?
BACKGROUND: The sodium/glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like-1 receptor agonists (GLP-1RA) are antidiabetic agents effective both in hemoglobin A1c (HbA1c) reduction (with a low risk of hypoglycemia) and cardiovascular event prevention. In patients with type 2 diabetes, the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672794/ https://www.ncbi.nlm.nih.gov/pubmed/33269065 http://dx.doi.org/10.4239/wjd.v11.i11.540 |
_version_ | 1783611206062309376 |
---|---|
author | Cigrovski Berkovic, Maja Bilic-Curcic, Ines Bozek, Tomislav Herman Mahecic, Davorka Klobucar Majanovic, Sanja Canecki-Varzic, Silvija Andric, Jelena Marusic, Srecko Mrzljak, Anna |
author_facet | Cigrovski Berkovic, Maja Bilic-Curcic, Ines Bozek, Tomislav Herman Mahecic, Davorka Klobucar Majanovic, Sanja Canecki-Varzic, Silvija Andric, Jelena Marusic, Srecko Mrzljak, Anna |
author_sort | Cigrovski Berkovic, Maja |
collection | PubMed |
description | BACKGROUND: The sodium/glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like-1 receptor agonists (GLP-1RA) are antidiabetic agents effective both in hemoglobin A1c (HbA1c) reduction (with a low risk of hypoglycemia) and cardiovascular event prevention. In patients with type 2 diabetes, the add-on value of combination therapy of GLP-1RA and an SGLT-2i seems promising. AIM: To investigate whether the efficacy of GLP-1RA and SGLT-2i combination observed in randomized controlled trials translates into therapeutic benefits in the Croatian population during routine clinical practice and follow-up. METHODS: We included 200 type 2 diabetes patients with poor glycemic control and analyzed the effects of treatment intensification with (1) GLP-1RA on top of SGLT-2i, (2) SGLT-2i on top of GLP-1RA compared to (3) simultaneous addition of both agents. The primary study endpoint was the proportion of participants with HbA1c < 7.0% and/or 5% bodyweight reduction. Secondary outcomes included changes in fasting plasma glucose (FPG), prandial plasma glucose, low-density lipoprotein cholesterol, estimated glomerular filtration rate (eGFR), and cardiovascular (CV) incidents assessment over a follow-up period of 12 mo. RESULTS: The majority of patients were over 65-years-old, had diabetes duration for more than 10 years. The initial body mass index was 39.41 ± 5.49 kg/m(2) and HbA1c 8.32 ± 1.26%. Around half of the patients in all three groups achieved target HbA1c below 7%. A more pronounced decrease in the HbA1c seen with simultaneous SGLT-2i and GLP-1RA therapy was a result of higher baseline HbA1c and not the effect of initiating combination therapy. The number of patients achieving FPG below 7.0 mmol/L was significantly higher in the SGLT-2i group (P = 0.021), and 5% weight loss was dominantly achieved in the simultaneous therapy group (P = 0.044). A composite outcome (reduction of HbA1c below 7% (53 mmol/mol) with 5% weight loss) was achieved in 32.3% of total patients included in the study. Only 18.2% of patients attained composite outcome defined as HbA1c below 7% (53 mmol/mol) with 5% weight loss and low-density lipoprotein cholesterol < 2.5 mmol/L. There were no significant differences between treatment groups. No differences were observed regarding CV incidents or eGFR according to treatment group over a follow-up period. CONCLUSION: Combination therapy with GLP-1RA and SGLT-2i is effective in terms of metabolic control, although it remains to be determined whether simultaneous or sequential intensification is better. |
format | Online Article Text |
id | pubmed-7672794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-76727942020-12-01 Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting? Cigrovski Berkovic, Maja Bilic-Curcic, Ines Bozek, Tomislav Herman Mahecic, Davorka Klobucar Majanovic, Sanja Canecki-Varzic, Silvija Andric, Jelena Marusic, Srecko Mrzljak, Anna World J Diabetes Observational Study BACKGROUND: The sodium/glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like-1 receptor agonists (GLP-1RA) are antidiabetic agents effective both in hemoglobin A1c (HbA1c) reduction (with a low risk of hypoglycemia) and cardiovascular event prevention. In patients with type 2 diabetes, the add-on value of combination therapy of GLP-1RA and an SGLT-2i seems promising. AIM: To investigate whether the efficacy of GLP-1RA and SGLT-2i combination observed in randomized controlled trials translates into therapeutic benefits in the Croatian population during routine clinical practice and follow-up. METHODS: We included 200 type 2 diabetes patients with poor glycemic control and analyzed the effects of treatment intensification with (1) GLP-1RA on top of SGLT-2i, (2) SGLT-2i on top of GLP-1RA compared to (3) simultaneous addition of both agents. The primary study endpoint was the proportion of participants with HbA1c < 7.0% and/or 5% bodyweight reduction. Secondary outcomes included changes in fasting plasma glucose (FPG), prandial plasma glucose, low-density lipoprotein cholesterol, estimated glomerular filtration rate (eGFR), and cardiovascular (CV) incidents assessment over a follow-up period of 12 mo. RESULTS: The majority of patients were over 65-years-old, had diabetes duration for more than 10 years. The initial body mass index was 39.41 ± 5.49 kg/m(2) and HbA1c 8.32 ± 1.26%. Around half of the patients in all three groups achieved target HbA1c below 7%. A more pronounced decrease in the HbA1c seen with simultaneous SGLT-2i and GLP-1RA therapy was a result of higher baseline HbA1c and not the effect of initiating combination therapy. The number of patients achieving FPG below 7.0 mmol/L was significantly higher in the SGLT-2i group (P = 0.021), and 5% weight loss was dominantly achieved in the simultaneous therapy group (P = 0.044). A composite outcome (reduction of HbA1c below 7% (53 mmol/mol) with 5% weight loss) was achieved in 32.3% of total patients included in the study. Only 18.2% of patients attained composite outcome defined as HbA1c below 7% (53 mmol/mol) with 5% weight loss and low-density lipoprotein cholesterol < 2.5 mmol/L. There were no significant differences between treatment groups. No differences were observed regarding CV incidents or eGFR according to treatment group over a follow-up period. CONCLUSION: Combination therapy with GLP-1RA and SGLT-2i is effective in terms of metabolic control, although it remains to be determined whether simultaneous or sequential intensification is better. Baishideng Publishing Group Inc 2020-11-15 2020-11-15 /pmc/articles/PMC7672794/ /pubmed/33269065 http://dx.doi.org/10.4239/wjd.v11.i11.540 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Observational Study Cigrovski Berkovic, Maja Bilic-Curcic, Ines Bozek, Tomislav Herman Mahecic, Davorka Klobucar Majanovic, Sanja Canecki-Varzic, Silvija Andric, Jelena Marusic, Srecko Mrzljak, Anna Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting? |
title | Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting? |
title_full | Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting? |
title_fullStr | Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting? |
title_full_unstemmed | Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting? |
title_short | Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting? |
title_sort | glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting? |
topic | Observational Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672794/ https://www.ncbi.nlm.nih.gov/pubmed/33269065 http://dx.doi.org/10.4239/wjd.v11.i11.540 |
work_keys_str_mv | AT cigrovskiberkovicmaja glucagonlike1receptoragonistsandsodiumglucosecotransporter2inhibitorscombinationareweexploitingtheirfullpotentialinareallifesetting AT biliccurcicines glucagonlike1receptoragonistsandsodiumglucosecotransporter2inhibitorscombinationareweexploitingtheirfullpotentialinareallifesetting AT bozektomislav glucagonlike1receptoragonistsandsodiumglucosecotransporter2inhibitorscombinationareweexploitingtheirfullpotentialinareallifesetting AT hermanmahecicdavorka glucagonlike1receptoragonistsandsodiumglucosecotransporter2inhibitorscombinationareweexploitingtheirfullpotentialinareallifesetting AT klobucarmajanovicsanja glucagonlike1receptoragonistsandsodiumglucosecotransporter2inhibitorscombinationareweexploitingtheirfullpotentialinareallifesetting AT caneckivarzicsilvija glucagonlike1receptoragonistsandsodiumglucosecotransporter2inhibitorscombinationareweexploitingtheirfullpotentialinareallifesetting AT andricjelena glucagonlike1receptoragonistsandsodiumglucosecotransporter2inhibitorscombinationareweexploitingtheirfullpotentialinareallifesetting AT marusicsrecko glucagonlike1receptoragonistsandsodiumglucosecotransporter2inhibitorscombinationareweexploitingtheirfullpotentialinareallifesetting AT mrzljakanna glucagonlike1receptoragonistsandsodiumglucosecotransporter2inhibitorscombinationareweexploitingtheirfullpotentialinareallifesetting |